object  	object_drugbank	precipitant	precipitant_drugbank	Effect	Mechanism	Related Drugs	Options	
AMIODARONE	DB01118	LEVOFLOXACIN	DB01137	Increased risk of TdP and/or QTc prolongation on ECG	Concomitant blockade of cardiac potassium channels	"�Azithromycin (Zithromax�), clarithromycin (Biaxin�), erythromycin (E-Mycin�), and telithromycin (Ketek�) also have a possible risk of TDP and/or QTc prolongation on ECG"	"Usually Avoid �Consider Alternatives: Alternative antimicrobials include ciprofloxacin (relatively lower risk QTc prolongation than other quinolones), penicillins, and cephalosporins. See www.azcert.org for QT drug lists by risk group"	
AMIODARONE	DB01118	GEMIFLOXACIN	DB01155	Increased risk of TdP and/or QTc prolongation on ECG	Concomitant blockade of cardiac potassium channels	"�Azithromycin (Zithromax�), clarithromycin (Biaxin�), erythromycin (E-Mycin�), and telithromycin (Ketek�) also have a possible risk of TDP and/or QTc prolongation on ECG"	"Usually Avoid �Consider Alternatives: Alternative antimicrobials include ciprofloxacin (relatively lower risk QTc prolongation than other quinolones), penicillins, and cephalosporins. See www.azcert.org for QT drug lists by risk group"	
AMIODARONE	DB01118	MOXIFLOXACIN	DB00218	Increased risk of TdP and/or QTc prolongation on ECG	Concomitant blockade of cardiac potassium channels	"�Azithromycin (Zithromax�), clarithromycin (Biaxin�), erythromycin (E-Mycin�), and telithromycin (Ketek�) also have a possible risk of TDP and/or QTc prolongation on ECG"	"Usually Avoid �Consider Alternatives: Alternative antimicrobials include ciprofloxacin (relatively lower risk QTc prolongation than other quinolones), penicillins, and cephalosporins. See www.azcert.org for QT drug lists by risk group"	
AMIODARONE	DB01118	OFLOXACIN	DB01165	Increased risk of TdP and/or QTc prolongation on ECG	Concomitant blockade of cardiac potassium channels	"�Azithromycin (Zithromax�), clarithromycin (Biaxin�), erythromycin (E-Mycin�), and telithromycin (Ketek�) also have a possible risk of TDP and/or QTc prolongation on ECG"	"Usually Avoid �Consider Alternatives: Alternative antimicrobials include ciprofloxacin (relatively lower risk QTc prolongation than other quinolones), penicillins, and cephalosporins. See www.azcert.org for QT drug lists by risk group"	
AMIODARONE	DB01118	CIPROFLOXACIN	DB00537	Increased risk of TdP and/or QTc prolongation on ECG	Concomitant blockade of cardiac potassium channels	"�Azithromycin (Zithromax�), clarithromycin (Biaxin�), erythromycin (E-Mycin�), and telithromycin (Ketek�) also have a possible risk of TDP and/or QTc prolongation on ECG"	"Usually Avoid �Consider Alternatives: Alternative antimicrobials include ciprofloxacin (relatively lower risk QTc prolongation than other quinolones), penicillins, and cephalosporins. See www.azcert.org for QT drug lists by risk group"	
CARBAMAZEPINE	DB00564	CLARITHROMYCIN	DB01211	Increased carbamazepine concentrations and risk of carbamazepine toxicity	Inhibition of carbamazepine metabolism by CYP3A4	�Azithromycin (Zithromax�) does�not�appear to inhibit CYP3A4	"Take Precautions �Consider Alternatives: Consider alternative antimicrobials (e.g., azithromycin, quinolones, 2nd/3rd generation cephalosporins, penicillin) �Monitor: If alternatives are not appropriate, monitor carbamazepine concentrations (e.g., within 24 hours) and consider temporary downward adjustment of the carbamazepine dosage (e.g., by 30-50%). Warn patients about symptoms of carbamazepine toxicity (e.g., nausea, vomiting, dizziness, drowsiness, headache, diplopia, confusion). Also monitor for altered carbamazepine effect when clarithromycin or erythromycin are changed in dosage or discontinued.If carbamazepine is started in the presence of one of these agents, consider conservative initial carbamazepine dosing."	
CARBAMAZEPINE	DB00564	ERYTHROMYCIN	DB00199	Increased carbamazepine concentrations and risk of carbamazepine toxicity	Inhibition of carbamazepine metabolism by CYP3A4	�Azithromycin (Zithromax�) does�not�appear to inhibit CYP3A4	"Take Precautions �Consider Alternatives: Consider alternative antimicrobials (e.g., azithromycin, quinolones, 2nd/3rd generation cephalosporins, penicillin) �Monitor: If alternatives are not appropriate, monitor carbamazepine concentrations (e.g., within 24 hours) and consider temporary downward adjustment of the carbamazepine dosage (e.g., by 30-50%). Warn patients about symptoms of carbamazepine toxicity (e.g., nausea, vomiting, dizziness, drowsiness, headache, diplopia, confusion). Also monitor for altered carbamazepine effect when clarithromycin or erythromycin are changed in dosage or discontinued.If carbamazepine is started in the presence of one of these agents, consider conservative initial carbamazepine dosing."	
CARBAMAZEPINE	DB00564	TELITHROMYCIN	DB00976	Increased carbamazepine concentrations and risk of carbamazepine toxicity	Inhibition of carbamazepine metabolism by CYP3A4	�Azithromycin (Zithromax�) does�not�appear to inhibit CYP3A4	"Take Precautions �Consider Alternatives: Consider alternative antimicrobials (e.g., azithromycin, quinolones, 2nd/3rd generation cephalosporins, penicillin) �Monitor: If alternatives are not appropriate, monitor carbamazepine concentrations (e.g., within 24 hours) and consider temporary downward adjustment of the carbamazepine dosage (e.g., by 30-50%). Warn patients about symptoms of carbamazepine toxicity (e.g., nausea, vomiting, dizziness, drowsiness, headache, diplopia, confusion). Also monitor for altered carbamazepine effect when clarithromycin or erythromycin are changed in dosage or discontinued.If carbamazepine is started in the presence of one of these agents, consider conservative initial carbamazepine dosing."	
CLOPIDOGREL	DB00758	OMEPRAZOLE	DB00338	Decreased concentrations of clopidogrel active metabolite and decreased antiplatelet effects	Inhibition of clopidogrel (prodrug) metabolism to active metabolite by CYP2C19	�Esomeprazole (Nexium�) is thought to also inhibit CYP2C19; insufficient data regarding other PPIs �Cimetidine (Tagamet�) inhibits CYP2C19	Usually Avoid �Consider Alternatives: Consider an alternative proton-pump inhibitor (except esomeprazole) Other alternatives include H2 blockers (except cimetidine).	
DIGOXIN 	DB00390	CLARITHROMYCIN  	DB01211	Increased digoxin concentrations and risk of digoxin toxicity	Inhibition of digoxin transport by P-glycoprotein resulting in reduced renal and nonrenal elimination of digoxin		Isolated reports of digoxin toxicity have been associated with azithromycin (Zithromax�) therapy	"Take Precautions �Consider Alternatives: Consider alternative antimicrobials that do not inhibit P-glycoprotein (e.g., 2nd/3rd generation cephalosporins, penicillin, quinolones) �Monitor: If alternatives are not appropriate, evaluate patients for evidence of digoxin toxicity (e.g., nausea, malaise, fatigue visual, changes, headache, arrhythmias), with downward digoxin dosage adjustments as needed. Also monitor for altered digoxin effect when clarithromycin or erythromycin are changed in dosage or discontinued. If digoxin is started in the presence of one of these agents, consider conservative initial digoxin dosing."
DIGOXIN	DB00390	ERYTHROMYCIN   	DB00199	Increased digoxin concentrations and risk of digoxin toxicity	Inhibition of digoxin transport by P-glycoprotein resulting in reduced renal and nonrenal elimination of digoxin		Isolated reports of digoxin toxicity have been associated with azithromycin (Zithromax�) therapy	"Take Precautions �Consider Alternatives: Consider alternative antimicrobials that do not inhibit P-glycoprotein (e.g., 2nd/3rd generation cephalosporins, penicillin, quinolones) �Monitor: If alternatives are not appropriate, evaluate patients for evidence of digoxin toxicity (e.g., nausea, malaise, fatigue visual, changes, headache, arrhythmias), with downward digoxin dosage adjustments as needed. Also monitor for altered digoxin effect when clarithromycin or erythromycin are changed in dosage or discontinued. If digoxin is started in the presence of one of these agents, consider conservative initial digoxin dosing."
DIGOXIN	DB00391	ITRACONAZOLE    	DB01167	Increased digoxin concentrations and risk of digoxin toxicity	Inhibition of digoxin transport by P-glycoprotein resulting in reduced renal and nonrenal elimination of digoxin	"�Voriconazole (Vfend�) and the non-azole antifungal, terbinafine (Lamisil�), do not appear to inhibit P-glycoprotein �Data are lacking regarding fluconazole"	"Take Precautions �Consider Alternatives: Consider alternative antifungal agents (e.g., voriconazole or terbinafine) �Monitor: If alternatives are not appropriate, monitor patients closely for evidence of digoxin toxicity (e.g., nausea, malaise, fatigue visual, changes, headache, arrhythmias), with downward digoxin dosage adjustments as necessary. Also monitor for altered digoxin effect when itraconazole, ketoconazole, or posaconazole are changed in dosage or discontinued. If digoxin is started in the presence of one of these agents, consider conservative initial digoxin dosing."	
DIGOXIN	DB00392	KETOCONAZOLE    	DB01026	Increased digoxin concentrations and risk of digoxin toxicity	Inhibition of digoxin transport by P-glycoprotein resulting in reduced renal and nonrenal elimination of digoxin	"�Voriconazole (Vfend�) and the non-azole antifungal, terbinafine (Lamisil�), do not appear to inhibit P-glycoprotein �Data are lacking regarding fluconazole"	"Take Precautions �Consider Alternatives: Consider alternative antifungal agents (e.g., voriconazole or terbinafine) �Monitor: If alternatives are not appropriate, monitor patients closely for evidence of digoxin toxicity (e.g., nausea, malaise, fatigue visual, changes, headache, arrhythmias), with downward digoxin dosage adjustments as necessary. Also monitor for altered digoxin effect when itraconazole, ketoconazole, or posaconazole are changed in dosage or discontinued. If digoxin is started in the presence of one of these agents, consider conservative initial digoxin dosing."	
DIGOXIN	DB00393	POSACONAZOLE    	DB01263	Increased digoxin concentrations and risk of digoxin toxicity	Inhibition of digoxin transport by P-glycoprotein resulting in reduced renal and nonrenal elimination of digoxin	"�Voriconazole (Vfend�) and the non-azole antifungal, terbinafine (Lamisil�), do not appear to inhibit P-glycoprotein �Data are lacking regarding fluconazole"	"Take Precautions �Consider Alternatives: Consider alternative antifungal agents (e.g., voriconazole or terbinafine) �Monitor: If alternatives are not appropriate, monitor patients closely for evidence of digoxin toxicity (e.g., nausea, malaise, fatigue visual, changes, headache, arrhythmias), with downward digoxin dosage adjustments as necessary. Also monitor for altered digoxin effect when itraconazole, ketoconazole, or posaconazole are changed in dosage or discontinued. If digoxin is started in the presence of one of these agents, consider conservative initial digoxin dosing."	
SIMVASTATIN	DB00641	AMIODARONE	DB01118	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of metabolism of simvastatin/ lovastatin by CYP3A4	"�Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4; however cases of myopathy with CYP3A4 inhibitors have been reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternatives: Preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. Predisposing risk factors for rhabdomyolysis include advanced age (>65 years), uncontrolled hypothyroidism, and renal impairment. �Monitor: If alternative statins are not appropriate, monitor the patient for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine). The simvastatin dose should not exceed 20 mg/day in combination with amiodarone."	
ATORVASTATIN CALCIUM	DB01076	ITRACONAZOLE    	DB01167	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
ATORVASTATIN CALCIUM	DB01077	KETOCONAZOLE	DB01026	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
ATORVASTATIN CALCIUM	DB01078	POSACONAZOLE	DB01263	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
ATORVASTATIN CALCIUM	DB01079	VORICONAZOLE	DB00582	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
ATORVASTATIN CALCIUM	DB01080	FLUCONAZOLE	DB00196	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
FLUVASTATIN	DB01095	ITRACONAZOLE	DB01167	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
FLUVASTATIN	DB01095	KETOCONAZOLE	DB01026	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
FLUVASTATIN	DB01095	POSACONAZOLE	DB01263	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
FLUVASTATIN	DB01095	VORICONAZOLE	DB00582	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
FLUVASTATIN	DB01095	FLUCONAZOLE	DB00196	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
LOVASTATIN	DB00227	ITRACONAZOLE	DB01167	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
LOVASTATIN	DB00227	KETOCONAZOLE	DB01026	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
LOVASTATIN	DB00227	POSACONAZOLE	DB01263	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
LOVASTATIN	DB00227	VORICONAZOLE	DB00582	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
LOVASTATIN	DB00227	FLUCONAZOLE	DB00196	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
PRAVASTATIN	DB00175	ITRACONAZOLE	DB01167	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
PRAVASTATIN	DB00175	KETOCONAZOLE	DB01026	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
PRAVASTATIN	DB00175	POSACONAZOLE	DB01263	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
PRAVASTATIN	DB00175	VORICONAZOLE	DB00582	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
PRAVASTATIN	DB00175	FLUCONAZOLE	DB00196	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
ROSUVASTATIN	DB01098	ITRACONAZOLE	DB01167	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
ROSUVASTATIN	DB01098	KETOCONAZOLE	DB01026	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
ROSUVASTATIN	DB01098	POSACONAZOLE	DB01263	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
ROSUVASTATIN	DB01098	VORICONAZOLE	DB00582	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
ROSUVASTATIN	DB01098	FLUCONAZOLE	DB00196	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
SIMVASTATIN	DB00641	ITRACONAZOLE	DB01167	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
SIMVASTATIN	DB00641	KETOCONAZOLE	DB01026	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
SIMVASTATIN	DB00641	POSACONAZOLE	DB01263	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
SIMVASTATIN	DB00641	VORICONAZOLE	DB00582	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
SIMVASTATIN	DB00641	FLUCONAZOLE	DB00196	Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis	Inhibition of simvastatin/ lovastatin metabolism by CYP3A4	"Antifungal Agents �Terbinafine (Lamisil�) does not inhibit CYP3A4 �Ciclopirox nail lacquer (Penlac�) is not appreciably absorbed Statins �Atorvastatin (Lipitor�) undergoes less metabolism by CYP3A4 but cases of myopathy with CYP3A4 inhibitors reported �Fluvastatin (Lescol�), rosuvastatin (Crestor�), and pravastatin (Pravachol�) arenot metabolized by CYP3A4"	"Usually Avoid �Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. �Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. �Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. �Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine)."	
TAMOXIFEN	DB00675	BUPROPION	DB01156	Decreased clinical effectiveness of tamoxifen (decreased disease-free survival); people with �normal� CYP2D6 activity (extensive metabolizers) would be at risk of this interaction	Inhibition of activation of tamoxifen (prodrug) to its major active metabolite by CYP2D6	"�Citalopram (Celexa�), desvenlafaxine (Pristiq�), escitalopram (Lexapro�), and sertraline (Zoloft�), are weak inhibitors of CYP2D6 �Fluvoxamine (Luvox�) and venlafaxine (Effexor�) do not significantly inhibit CYP2D6"	"Take Precautions �Consider Alternatives: Preferable antidepressant alternatives are citalopram, desvenlafaxine, escitalopram, fluvoxamine, sertraline, and venlafaxine."	
TAMOXIFEN	DB00675	DULOXETINE	DB00476	Decreased clinical effectiveness of tamoxifen (decreased disease-free survival); people with �normal� CYP2D6 activity (extensive metabolizers) would be at risk of this interaction	Inhibition of activation of tamoxifen (prodrug) to its major active metabolite by CYP2D6	"�Citalopram (Celexa�), desvenlafaxine (Pristiq�), escitalopram (Lexapro�), and sertraline (Zoloft�), are weak inhibitors of CYP2D6 �Fluvoxamine (Luvox�) and venlafaxine (Effexor�) do not significantly inhibit CYP2D6"	"Take Precautions �Consider Alternatives: Preferable antidepressant alternatives are citalopram, desvenlafaxine, escitalopram, fluvoxamine, sertraline, and venlafaxine."	
TAMOXIFEN	DB00675	FLUOXETINE	DB00472	Decreased clinical effectiveness of tamoxifen (decreased disease-free survival); people with �normal� CYP2D6 activity (extensive metabolizers) would be at risk of this interaction	Inhibition of activation of tamoxifen (prodrug) to its major active metabolite by CYP2D6	"�Citalopram (Celexa�), desvenlafaxine (Pristiq�), escitalopram (Lexapro�), and sertraline (Zoloft�), are weak inhibitors of CYP2D6 �Fluvoxamine (Luvox�) and venlafaxine (Effexor�) do not significantly inhibit CYP2D6"	"Take Precautions �Consider Alternatives: Preferable antidepressant alternatives are citalopram, desvenlafaxine, escitalopram, fluvoxamine, sertraline, and venlafaxine."	
TAMOXIFEN	DB00675	PAROXETINE	DB00715	Decreased clinical effectiveness of tamoxifen (decreased disease-free survival); people with �normal� CYP2D6 activity (extensive metabolizers) would be at risk of this interaction	Inhibition of activation of tamoxifen (prodrug) to its major active metabolite by CYP2D6	"�Citalopram (Celexa�), desvenlafaxine (Pristiq�), escitalopram (Lexapro�), and sertraline (Zoloft�), are weak inhibitors of CYP2D6 �Fluvoxamine (Luvox�) and venlafaxine (Effexor�) do not significantly inhibit CYP2D6"	"Take Precautions �Consider Alternatives: Preferable antidepressant alternatives are citalopram, desvenlafaxine, escitalopram, fluvoxamine, sertraline, and venlafaxine."	
WARFARIN	DB00682	AMIODARONE	DB01118	Increased warfarin concentrations and bleeding risk	Inhibition of warfarin metabolism by CYP2C9	�Not applicable	"Take Precautions �Monitor: Increase the frequency of INR monitoring when amiodarone is started, stopped, or changed in dosage. The maximal effect of the interaction can take 8-12 weeks. The warfarin dosage may need to be reduced by 30%-50% during concurrent therapy. For patients stabilized on amiodarone, begin warfarin therapy with conservative doses until response is established."	
WARFARIN	DB00682	FLUCONAZOLE	DB00196	Increased warfarin concentrations and bleeding risk	Inhibition of warfarin metabolism by CYP2C9	"�Itraconazole (Sporanox�), ketoconazole (Nizoral�), posaconazole (Noxafil�), terbinafine (Lamisil�) do not appear to inhibit CYP2C9"	"Usually Avoid �Consider Alternatives: Itraconazole, ketoconazole, posaconazole, and terbinafine are preferable alternatives. �Monitor: Carefully monitor for an altered warfarin response if an interacting azole antifungal is started, stopped, or changed in dosage. A change in the warfarin dosage may be necessary. For patients already receiving one of the precipitant drugs, begin warfarin therapy with conservative doses until response is established."	
WARFARIN	DB00682	MICONAZOLE	DB01110	Increased warfarin concentrations and bleeding risk	Inhibition of warfarin metabolism by CYP2C10	"�Itraconazole (Sporanox�), ketoconazole (Nizoral�), posaconazole (Noxafil�), terbinafine (Lamisil�) do not appear to inhibit CYP2C10"	"Usually Avoid �Consider Alternatives: Itraconazole, ketoconazole, posaconazole, and terbinafine are preferable alternatives. �Monitor: Carefully monitor for an altered warfarin response if an interacting azole antifungal is started, stopped, or changed in dosage. A change in the warfarin dosage may be necessary. For patients already receiving one of the precipitant drugs, begin warfarin therapy with conservative doses until response is established."	
WARFARIN	DB00682	VORICONAZOLE	DB00582	Increased warfarin concentrations and bleeding risk	Inhibition of warfarin metabolism by CYP2C11	"�Itraconazole (Sporanox�), ketoconazole (Nizoral�), posaconazole (Noxafil�), terbinafine (Lamisil�) do not appear to inhibit CYP2C11"	"Usually Avoid �Consider Alternatives: Itraconazole, ketoconazole, posaconazole, and terbinafine are preferable alternatives. �Monitor: Carefully monitor for an altered warfarin response if an interacting azole antifungal is started, stopped, or changed in dosage. A change in the warfarin dosage may be necessary. For patients already receiving one of the precipitant drugs, begin warfarin therapy with conservative doses until response is established."	
WARFARIN	DB00682	CARBAMAZEPINE	DB00564	Decreased warfarin concentrations and warfarin effects	Induction of warfarin metabolism	"�Other anticonvulsant enzyme inducers that can also reduce the anticoagulant effect of warfarin include barbiturates, oxcarbazepine (Trileptal�), phenytoin (Dilantin�), and primidone (Mysoline�)"	"Take Precautions Monitor: If concurrent use is necessary, monitor for altered warfarin response if the inducer is started, stopped, or changed in dosage. Enzyme induction is often gradual and several weeks of more frequent monitoring is recommended. For patients already receiving carbamazepine, begin warfarin therapy with conservative doses until response is established."	
WARFARIN	DB00682	GEMFIBROZIL	DB01241	Increased warfarin effect and bleeding risk	Not established	�See warfarin and statins �An extended-release niacin product (Niaspan�) is not known to interact with warfarin �Gemfibrozil (Lopid�) and fenofibrate (Tricor�) inhibit CYP2C9 and may increase bleeding risk �Cholestyramine (Questran�) and colestipol (Colestid�) may reduce the effect of warfarin	"Usually Avoid �Consider Alternatives: Atorvastatin and pravastatin appear to be safer alteratives. Extended-release niacin is another alternative. �Monitor: If alternatives are not appropriate, carefully monitor the INR if a fibrate is started, stopped, or changed in dosage and adjust the warfarin dose accordingly. If warfarin is started in a patient receiving a fibrate, conservative doses of warfarin should be used until response is established"	
WARFARIN	DB00682	FENOFIBRATE	DB01039	Increased warfarin effect and bleeding risk	Not established	�See warfarin and statins �An extended-release niacin product (Niaspan�) is not known to interact with warfarin �Gemfibrozil (Lopid�) and fenofibrate (Tricor�) inhibit CYP2C9 and may increase bleeding risk �Cholestyramine (Questran�) and colestipol (Colestid�) may reduce the effect of warfarin	"Usually Avoid �Consider Alternatives: Atorvastatin and pravastatin appear to be safer alteratives. Extended-release niacin is another alternative. �Monitor: If alternatives are not appropriate, carefully monitor the INR if a fibrate is started, stopped, or changed in dosage and adjust the warfarin dose accordingly. If warfarin is started in a patient receiving a fibrate, conservative doses of warfarin should be used until response is established"	
WARFARIN	DB00682	CELECOXIB	DB00482	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	DICLOFENAC	DB00586	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	DIFLUNISAL	DB00861	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	ETODOLAC	DB00749	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	FENOPROFEN	DB00573	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	FLURBIPROFEN	DB00712	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	IBUPROFEN	DB01050	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	INDOMETHACIN	DB00328	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	KETOPROFEN	DB01009	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	KETOROLAC	DB00465	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	MEFENAMIC ACID	DB00784	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	MELOXICAM	DB00814	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	NABUMETONE	DB00461	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	NAPROXEN	DB00788	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	OXAPROZIN	DB00991	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	PIROXICAM	DB00554	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	SULINDAC	DB00605	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	TOLMETIN	DB00500	Additive risk of bleeding	�Antiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. �Some individual NSAIDs may also alter the pharmacokinetics of warfarin	"�Opioid analgesics are not known to interact with warfarin �Acetaminophen (Tylenol�) may alter the warfarin response but the effect is relatively small. �Antiplatelet therapy with aspirin primarily increases the risk of minor bleeding �Non-acetylated salicylates (e.g., salsalate [Disalcid]) may be safer than traditional NSAIDs �COX-2 inhibitors do not affect platelet function and probably cause less GI erosion but no evidence of decreased GI bleeding risk"	"Usually Avoid �Consider Alternatives: A non-NSAID alternative such as acetaminophen or opioid analgesics is preferred. To be cautious, limit the acetaminophen dose to 2 g/day for no more than 7 days. INR should be monitored closely when acetaminophen exceeds 2 g/day or chronic use >7 days occurs. �Monitor: If any NSAID is used with warfarin, monitor carefully for evidence of bleeding, especially from the GI tract."	
WARFARIN	DB00682	FLUVASTATIN	DB01095	Increased warfarin concentrations and bleeding risk	Inhibition of warfarin metabolism by CYP2C9 is proposed	�See warfarin and fibrates �Atorvastatin (Lipitor�) and pravastatin (Pravachol�) are not known to interact with warfarin	"Take Precautions �Consider Alternatives: Atorvastatin and pravastatin appear to be safer alteratives �Monitor: If alternatives are not appropriate, carefully monitor the INR if these agents are started, stopped, or changed in dosage and adjust the warfarin dose accordingly. If warfarin is started in a patient receiving these agents conservative doses of warfarin should be used until response is established."	
WARFARIN	DB00682	LOVASTATIN	DB00227	Increased warfarin concentrations and bleeding risk	Inhibition of warfarin metabolism by CYP2C9 is proposed	�See warfarin and fibrates �Atorvastatin (Lipitor�) and pravastatin (Pravachol�) are not known to interact with warfarin	"Take Precautions �Consider Alternatives: Atorvastatin and pravastatin appear to be safer alteratives �Monitor: If alternatives are not appropriate, carefully monitor the INR if these agents are started, stopped, or changed in dosage and adjust the warfarin dose accordingly. If warfarin is started in a patient receiving these agents conservative doses of warfarin should be used until response is established."	
WARFARIN	DB00682	ROSUVASTATIN	DB01098	Increased warfarin concentrations and bleeding risk	Inhibition of warfarin metabolism by CYP2C9 is proposed	�See warfarin and fibrates �Atorvastatin (Lipitor�) and pravastatin (Pravachol�) are not known to interact with warfarin	"Take Precautions �Consider Alternatives: Atorvastatin and pravastatin appear to be safer alteratives �Monitor: If alternatives are not appropriate, carefully monitor the INR if these agents are started, stopped, or changed in dosage and adjust the warfarin dose accordingly. If warfarin is started in a patient receiving these agents conservative doses of warfarin should be used until response is established."	
WARFARIN	DB00682	SIMVASTATIN	DB00641	Increased warfarin concentrations and bleeding risk	Inhibition of warfarin metabolism by CYP2C9 is proposed	�See warfarin and fibrates �Atorvastatin (Lipitor�) and pravastatin (Pravachol�) are not known to interact with warfarin	"Take Precautions �Consider Alternatives: Atorvastatin and pravastatin appear to be safer alteratives �Monitor: If alternatives are not appropriate, carefully monitor the INR if these agents are started, stopped, or changed in dosage and adjust the warfarin dose accordingly. If warfarin is started in a patient receiving these agents conservative doses of warfarin should be used until response is established."	
WARFARIN	DB00682	SULFAMETHOXAZOLE/TRIMETHOPRIM  	DB01015	Increased warfarin concentrations and bleeding risk	Inhibition of warfarin metabolism by CYP2C9	"�Oral penicillin, amoxicillin, ampicillin, and oral cephalosporins and penicillins havenot been shown to interact with warfarin �Quinolones and macrolides have been reported to increase the anticoagulant effects of warfarin"	"Usually Avoid �Consider Alternatives: Oral penicillins and cephalosporins are preferred alternatives. Quinolones and macrolides may be relatively safer to use in combination with warfarin than sulfamethoxazole or metronidazole. �Monitor: When alternatives are not appropriate, carefully monitor the INR and for signs of bleeding. The warfarin dosage may need to be temporarily reduced. If warfarin is started in a patient receiving these agents conservative doses of warfarin should be used until response is established. Also monitor for decreased anticoagulant effect after antibiotic therapy is discontinued. �Note:Nearly all antibiotics have been reported in isolated cases to interact with warfarin; caution should be used when adding any antibiotic to a patient on warfarin therapy."	
WARFARIN	DB00682	METRONIDAZOLE	DB00916	Increased warfarin concentrations and bleeding risk	Inhibition of warfarin metabolism by CYP2C9	"�Oral penicillin, amoxicillin, ampicillin, and oral cephalosporins and penicillins havenot been shown to interact with warfarin �Quinolones and macrolides have been reported to increase the anticoagulant effects of warfarin"	"Usually Avoid �Consider Alternatives: Oral penicillins and cephalosporins are preferred alternatives. Quinolones and macrolides may be relatively safer to use in combination with warfarin than sulfamethoxazole or metronidazole. �Monitor: When alternatives are not appropriate, carefully monitor the INR and for signs of bleeding. The warfarin dosage may need to be temporarily reduced. If warfarin is started in a patient receiving these agents conservative doses of warfarin should be used until response is established. Also monitor for decreased anticoagulant effect after antibiotic therapy is discontinued. �Note:Nearly all antibiotics have been reported in isolated cases to interact with warfarin; caution should be used when adding any antibiotic to a patient on warfarin therapy."	
WARFARIN	DB00682	LEVOTHYROXINE	DB00451	Increased bleeding risk	An accelerated depletion of vitamin K-dependent clotting factors as a result of thyroid hormone administration has been proposed	"Take Precautions �Monitor: For patients on a therapeutic dose of warfarin, more frequent INR monitoring is required (e.g., day 4, day 7, and weekly thereafter or as clinically indicated) if thyroid hormone therapy is started. In such cases, adownward adjustment of the warfarin dosage will often be needed to avoid excessive anticoagulation and bleeding. The risk is probably minimal if warfarin therapy is started in a euthyroid patient stabilized on thyroid replacement therapy. However, conservative doses of warfarin should be used until response is established if warfarin is started in a patient receiving these agents."		
WARFARIN	DB00682	LIOTHYRONINE	DB00279	Increased bleeding risk	An accelerated depletion of vitamin K-dependent clotting factors as a result of thyroid hormone administration has been proposed	"Take Precautions �Monitor: For patients on a therapeutic dose of warfarin, more frequent INR monitoring is required (e.g., day 4, day 7, and weekly thereafter or as clinically indicated) if thyroid hormone therapy is started. In such cases, adownward adjustment of the warfarin dosage will often be needed to avoid excessive anticoagulation and bleeding. The risk is probably minimal if warfarin therapy is started in a euthyroid patient stabilized on thyroid replacement therapy. However, conservative doses of warfarin should be used until response is established if warfarin is started in a patient receiving these agents."		
WARFARIN	DB00682	LIOTRIX 	DB01583	Increased bleeding risk	An accelerated depletion of vitamin K-dependent clotting factors as a result of thyroid hormone administration has been proposed	"Take Precautions �Monitor: For patients on a therapeutic dose of warfarin, more frequent INR monitoring is required (e.g., day 4, day 7, and weekly thereafter or as clinically indicated) if thyroid hormone therapy is started. In such cases, adownward adjustment of the warfarin dosage will often be needed to avoid excessive anticoagulation and bleeding. The risk is probably minimal if warfarin therapy is started in a euthyroid patient stabilized on thyroid replacement therapy. However, conservative doses of warfarin should be used until response is established if warfarin is started in a patient receiving these agents."		
